Sartorius Stedim Biotech Stock Fundamentals
| SDMHF Stock | USD 205.00 1.95 0.94% |
Fundamental analysis of Sartorius Stedim allows traders to better anticipate movements in Sartorius Stedim's stock price by examining its financial health and performance throughout various phases of its business cycle.
Sartorius |
Sartorius Stedim Biotech Company Return On Equity Analysis
Sartorius Stedim's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Sartorius Stedim Return On Equity | 0.33 |
Most of Sartorius Stedim's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sartorius Stedim Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Sartorius Stedim Biotech has a Return On Equity of 0.3306. This is 101.38% lower than that of the Healthcare sector and 105.53% lower than that of the Medical Instruments & Supplies industry. The return on equity for all United States stocks is notably lower than that of the firm.
Sartorius Stedim Biotech Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Sartorius Stedim's current stock value. Our valuation model uses many indicators to compare Sartorius Stedim value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Sartorius Stedim competition to find correlations between indicators driving Sartorius Stedim's intrinsic value. More Info.Sartorius Stedim Biotech is rated below average in return on equity category among its peers. It is currently regarded as top stock in return on asset category among its peers reporting about 0.42 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Sartorius Stedim Biotech is roughly 2.38 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Sartorius Stedim's earnings, one of the primary drivers of an investment's value.Sartorius Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sartorius Stedim's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Sartorius Stedim could also be used in its relative valuation, which is a method of valuing Sartorius Stedim by comparing valuation metrics of similar companies.Sartorius Stedim is currently under evaluation in return on equity category among its peers.
Sartorius Fundamentals
| Return On Equity | 0.33 | |||
| Return On Asset | 0.14 | |||
| Profit Margin | 0.20 % | |||
| Operating Margin | 0.30 % | |||
| Current Valuation | 32.97 B | |||
| Shares Outstanding | 92.17 M | |||
| Shares Owned By Insiders | 73.81 % | |||
| Shares Owned By Institutions | 13.73 % | |||
| Price To Earning | 60.34 X | |||
| Price To Book | 13.58 X | |||
| Price To Sales | 9.62 X | |||
| Revenue | 2.89 B | |||
| Gross Profit | 1.55 B | |||
| EBITDA | 798.67 M | |||
| Net Income | 414.41 M | |||
| Cash And Equivalents | 161.7 M | |||
| Cash Per Share | 1.75 X | |||
| Total Debt | 521.07 M | |||
| Debt To Equity | 0.50 % | |||
| Current Ratio | 1.49 X | |||
| Book Value Per Share | 24.67 X | |||
| Cash Flow From Operations | 695.97 M | |||
| Earnings Per Share | 7.94 X | |||
| Price To Earnings To Growth | 3.43 X | |||
| Number Of Employees | 10.41 K | |||
| Beta | 0.45 | |||
| Market Capitalization | 34.9 B | |||
| Total Asset | 3.95 B | |||
| Z Score | 39.6 | |||
| Annual Yield | 0 % | |||
| Five Year Return | 0.50 % | |||
| Net Asset | 3.95 B |
About Sartorius Stedim Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sartorius Stedim Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sartorius Stedim using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sartorius Stedim Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Sartorius Stedim Biotech S.A. produces and sells instruments and consumables for the biopharmaceutical industry worldwide. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG. Sartorius Stedim operates under Medical Instruments Supplies classification in the United States and is traded on OTC Exchange. It employs 10409 people.
Currently Active Assets on Macroaxis
| VALE | Vale SA ADR | |
| EGY | Vaalco Energy | |
| CMCSA | Comcast Corp | |
| BTE | Baytex Energy Corp | |
| SOXS | Direxion Daily Semiconductor |
Other Information on Investing in Sartorius Pink Sheet
Sartorius Stedim financial ratios help investors to determine whether Sartorius Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Sartorius with respect to the benefits of owning Sartorius Stedim security.